Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

NCT01297244 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01297244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01297244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
October 31, 2012
Enrollment
105 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma